• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Great Debate: Molecular Testing and Extent of Surgery in Well-Differentiated Thyroid Cancer.

作者信息

Sturgeon Cord, Shaha Ashok R, Yip Linwah

机构信息

Section of Endocrine Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

Ann Surg Oncol. 2025 Apr 29. doi: 10.1245/s10434-025-17348-z.

DOI:10.1245/s10434-025-17348-z
PMID:40301207
Abstract
摘要

相似文献

1
Great Debate: Molecular Testing and Extent of Surgery in Well-Differentiated Thyroid Cancer.激烈辩论：高分化甲状腺癌的分子检测与手术范围
Ann Surg Oncol. 2025 Apr 29. doi: 10.1245/s10434-025-17348-z.
2
Role and Extent of Neck Dissection for Neck Lymph Node Metastases in Differentiated Thyroid Cancers.分化型甲状腺癌颈部淋巴结转移的颈部清扫术的作用及范围
Sisli Etfal Hastan Tip Bul. 2021 Dec 29;55(4):438-449. doi: 10.14744/SEMB.2021.76836. eCollection 2021.
3
[The extent of surgery for well-differentiated thyroid cancer related with surgical morbidity].[高分化甲状腺癌手术范围与手术并发症的关系]
Cir Cir. 2007 Mar-Apr;75(2):71-4.
4
Tumor size and molecular risk group are associated with differentiated thyroid cancer recurrence.肿瘤大小和分子风险分组与分化型甲状腺癌复发相关。
Surgery. 2025 Jan;177:108838. doi: 10.1016/j.surg.2024.06.066. Epub 2024 Oct 9.
5
Controversies and challenges in the management of well-differentiated thyroid cancer.分化型甲状腺癌管理中的争议与挑战
Indian J Surg. 2009 Dec;71(6):299-307. doi: 10.1007/s12262-009-0084-6. Epub 2010 Jan 13.
6
Management of thyroid nodules and surgery for differentiated thyroid cancer.甲状腺结节的管理和分化型甲状腺癌的手术治疗。
Clin Oncol (R Coll Radiol). 2010 Aug;22(6):405-12. doi: 10.1016/j.clon.2010.03.009. Epub 2010 Apr 8.
7
Extent of Surgery for Low-Risk Differentiated Thyroid Cancer.低危分化型甲状腺癌的手术范围。
Surg Clin North Am. 2019 Aug;99(4):599-610. doi: 10.1016/j.suc.2019.04.003. Epub 2019 May 13.
8
Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer.预后因素及风险分组在分化型甲状腺癌管理中的意义
Laryngoscope. 2004 Mar;114(3):393-402. doi: 10.1097/00005537-200403000-00001.
9
Prophylactic central lymph node dissection in differentiated thyroid cancer - benefits and risk.分化型甲状腺癌预防性中央区淋巴结清扫术——获益与风险。
Folia Med (Plovdiv). 2022 Jun 30;64(3):430-436. doi: 10.3897/folmed.64.e64030.
10
A clinical algorithm for fine-needle aspiration molecular testing effectively guides the appropriate extent of initial thyroidectomy.一项用于细针穿刺分子检测的临床算法可有效指导初始甲状腺切除术的适当范围。
Ann Surg. 2014 Jul;260(1):163-8. doi: 10.1097/SLA.0000000000000215.

本文引用的文献

1
Association Between Maternal Thyroid Hormone Concentration with Normal Thyroid Function During Pregnancy and Preschoolers' Glycolipid Metabolism: A Birth Cohort Study.孕期甲状腺功能正常的孕妇甲状腺激素浓度与学龄前儿童糖脂代谢之间的关联：一项出生队列研究
Thyroid. 2025 Apr;35(4):444-456. doi: 10.1089/thy.2024.0334. Epub 2025 Mar 7.
2
High Rates of Unnecessary Surgery for Indeterminate Thyroid Nodules in the Absence of Molecular Test and the Cost-Effectiveness of Utilizing Molecular Test in an Asian Population: A Decision Analysis.在缺乏分子检测的情况下，亚洲人群中不确定甲状腺结节的不必要手术高发生率以及使用分子检测的成本效益：一项决策分析。
Thyroid. 2025 Feb;35(2):166-176. doi: 10.1089/thy.2024.0436. Epub 2025 Jan 21.
3
Small Multi-Gene DNA Panel Can Aid in Reducing the Surgical Resection Rate and Predicting the Malignancy Risk of Thyroid Nodules.
多基因小 DNA 面板有助于降低甲状腺结节的手术切除率并预测其恶性风险。
Endocrinol Metab (Seoul). 2024 Oct;39(5):777-792. doi: 10.3803/EnM.2024.2034. Epub 2024 Oct 14.
4
Correlation of ultrasound-based TIRADS and the Bethesda system for reporting of thyroid cytopathology: A study in a tertiary care centre.基于超声的 TIRADS 与甲状腺细胞病理学报告的 Bethesda 系统的相关性：三级保健中心的研究。
Cytopathology. 2023 Nov;34(6):590-596. doi: 10.1111/cyt.13273. Epub 2023 Jul 20.
5
The 2023 Bethesda System for Reporting Thyroid Cytopathology.2023 年甲状腺细胞病理学报告的贝塞斯达系统。
Thyroid. 2023 Sep;33(9):1039-1044. doi: 10.1089/thy.2023.0141. Epub 2023 Jul 8.
6
Chronic Lymphocytic Thyroiditis May Limit the Utility of Molecular Testing in AUS/FLUS Thyroid Nodules.慢性淋巴细胞性甲状腺炎可能限制 AUS/FLUS 甲状腺结节中分子检测的应用。
J Surg Res. 2023 Sep;289:229-233. doi: 10.1016/j.jss.2023.03.034. Epub 2023 May 4.
7
Molecular Profiling of 50 734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management.50734 例 Bethesda III-VI 级甲状腺结节的 ThyroSeq v3 分子谱分析：对个体化管理的启示。
J Clin Endocrinol Metab. 2023 Oct 18;108(11):2999-3008. doi: 10.1210/clinem/dgad220.
8
Molecular Testing Predicts Incomplete Response to Initial Therapy in Differentiated Thyroid Carcinoma Without Lateral Neck or Distant Metastasis at Presentation: Retrospective Cohort Study.分子检测预测分化型甲状腺癌在初始治疗时无侧颈部或远处转移的不完全反应：回顾性队列研究。
Thyroid. 2023 Jun;33(6):705-714. doi: 10.1089/thy.2023.0060. Epub 2023 Apr 28.
9
Changes in thyroid nodule cytology rates after institutional implementation of the Thyroid Imaging Reporting and Data System.甲状腺影像学报告和数据系统实施后甲状腺结节细胞学检查率的变化。
Surgery. 2023 Jan;173(1):232-238. doi: 10.1016/j.surg.2022.06.061. Epub 2022 Oct 14.
10
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.达拉非尼联合曲美替尼治疗 BRAF V600E 突变型甲状腺未分化癌患者：来自 II 期 ROAR 篮子研究的更新分析。
Ann Oncol. 2022 Apr;33(4):406-415. doi: 10.1016/j.annonc.2021.12.014. Epub 2022 Jan 10.